CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 471 filers reported holding CRISPR THERAPEUTICS AG in Q3 2021. The put-call ratio across all filers is 1.71 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $67,000 | -65.5% | 600 | -50.0% | 0.00% | – |
| Q2 2021 | $194,000 | +32.9% | 1,200 | 0.0% | 0.00% | – |
| Q1 2021 | $146,000 | -85.6% | 1,200 | 0.0% | 0.00% | – |
| Q4 2020 | $1,011,000 | +405.5% | 1,200 | -50.0% | 0.00% | -100.0% |
| Q3 2020 | $200,000 | +13.6% | 2,400 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $176,000 | +245.1% | 2,400 | +100.0% | 0.00% | – |
| Q1 2020 | $51,000 | -30.1% | 1,200 | 0.0% | 0.00% | – |
| Q4 2019 | $73,000 | +942.9% | 1,200 | +627.3% | 0.00% | – |
| Q3 2019 | $7,000 | -87.7% | 165 | -86.2% | 0.00% | – |
| Q2 2019 | $57,000 | +32.6% | 1,200 | 0.0% | 0.00% | – |
| Q1 2019 | $43,000 | +26.5% | 1,200 | 0.0% | 0.00% | – |
| Q4 2018 | $34,000 | -35.8% | 1,200 | 0.0% | 0.00% | – |
| Q3 2018 | $53,000 | -25.4% | 1,200 | 0.0% | 0.00% | -100.0% |
| Q2 2018 | $71,000 | -9.0% | 1,200 | -29.4% | 0.00% | 0.0% |
| Q1 2018 | $78,000 | +387.5% | 1,700 | +142.9% | 0.00% | – |
| Q4 2017 | $16,000 | – | 700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |